Developing Sophisticated Allogeneic Cell Therapies
Caribou Biosciences is a clinical-stage CRISPR genome-editing biopharmaceutical company dedicated to developing transformative therapies for patients with devastating diseases. Its proprietary Cas12a chRDNA (CRISPR hybrid RNA-DNA) genome-editing platform enables superior precision for complex multiplex editing, including gene knockout and insertion. Caribou is advancing CB-010 and CB-011 as off-the-shelf allogeneic CAR-T cell therapies targeting hematologic malignancies.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountJul 2023
Jul 2021
Mar 2021
May 2016
Jan 2014
Create a free account to see which investors have funded this company.
Create Free Account
Developer of engineered cells as medicines to treat diseases by repairing or replacing cells for ...
Clinical-stage biotech developing next-generation CAR T-cell therapies for cancer patients aiming...
Biopharmaceutical company developing and commercializing RNAi therapeutics to treat genetically d...
Clinical-stage programmable cell therapy company developing engineered T-cell therapies for solid...
Develops Gene Writing technology and non-viral delivery to create in vivo genetic medicines for m...
San Diego-based clinical stage biopharmaceutical company focused on the development of small mole...
